GPR17 and multiple sclerosis: Since SDF-1 accumulates at the sites of demyelination and both GPR17 and chemokine receptors are recognized molecular targets in multiple sclerosis, these results suggest, for the first time, that a cross-talk between these receptors could play a role in the development of the neuroinflammatory milieu associated with demyelination lesions.